Probiodrug grants license to Ferring and Ortho McNeil Pharmaceuticals
Probiodrug’s P93/01 in clinics for the treatment of type 2 diabetes
Nimes, France // Halle (Saale), Germany //
Companies to apply Pep:trans technology to vectorise product into the brain to treat Multiple Sclerosis. probiodrug AG, a German biopharmaceutical company and Synt:em, a French biopharmaceutical company, announced today the signing of a collaboration agreement. The collaboration between the two companies is designed to combine probiodrug’s proprietary library of small molecules as effectors of certain drug targets with Synt:em’s Pep:transTM technology, a breakthrough reengineering technology that helps compounds to reach their target across complex biological membranes. The companies aim to develop NCE’s able to cross the blood brain barrier and thus to develop new effective drugs to treat diseases of the central nervous system (CNS), i.e. multiple sclerosis. They agreed to share developmental costs and revenues.
“We are pleased to enter into this collaboration agreement with Synt:em, which marks our efforts for the development of proprietary compounds targeting the CNS”, said Hans-Ulrich Demuth, Ph.D., CEO/CSO of Probiodrug. “Synt:em´s technologies are exceptionally suited to deliver drugs specifically to selected organs, e.g. the brain. Hence, vectorising our compounds will add specificity to the drugs and will lower the amount needed in the circulation for selective brain targeting.”
In commenting upon the deal, Michel Kaczorek, CEO and President of Synt:em expressed his delight on the arrangement: ” in this time of difficult time for financing, we confirm with this agreement in place, that our strategy to re-engineer drugs with Pep:transTM is an attractive way to develop a proprietary portfolio of compounds among which some are co-developed with partners in a risk balanced and cost efficient model. Our choice to collaborate with probiodrug is based on the very promising molecule they have discovered and the excellence of their science.”
Synt:em is a private French biopharmaceutical company that is focused on the discovery and development of novel Central Nervous System (CNS) medicines. Synt:em’s strategy is to take advantage of its complementary and proprietary technology platforms Pep:transTM and Acti:mapTM to develop an internal pipeline of drug candidates for the treatment of CNS disorders. In addition, Synt:em will continue establishing strong partnerships with Pharma and Biotech companies based on its Pep:transTM and Acti:mapTM technologies. For additional information about the company, please visit www.syntem.com.
About Probiodrug AG
Probiodrug AG is a biopharmaceutical company, that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of diabetes, obesity and other serious medical conditions based on its detailed understanding of the actions of DP IV and related enzymes.
Maisberger & Partner
Kirchenstr. 17 c-d
Tel.: +49 89 419599 23
Fax: +49 89 41 95 99 98 23
Dr. Konrad Glund
Tel.: +49 345 555 99 00
Fax: +49 345 555 99 01
Michel Kaczorek, Ph. D.
Parc Scientifique/Georges BesseParc
F-30035 Nimes Cedex 1
Tel.: +33 466 048 666
Fax: +33 466 048 667